Last reviewed · How we verify
The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma
This study aims to determine if the vacccine can be used safely in patients with advanced melanoma (cancer of the pigment cells) and whether the cells in this vaccine are capabale of producing immune responses against your own cancer.
Details
| Lead sponsor | Beth Israel Deaconess Medical Center |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | COMPLETED |
| Enrolment | 20 |
| Start date | 2000-07 |
| Completion | 2008-09-10 |
Conditions
- Metastatic Melanoma
Interventions
- DC/tumor fusion vaccine
Primary outcomes
- To assess the toxicity, cellular and humoral immunity and tumor response in patient with melanoma receiving the DC/tumor fusion vaccine — screening/baseline, treatment period and follow-up
Countries
United States